PPAR Research

PPAR Research / 2007 / Article
Special Issue

PPARs in Lung Biology and Disease

View this Special Issue

Review Article | Open Access

Volume 2007 |Article ID 63745 | 8 pages | https://doi.org/10.1155/2007/63745

Peroxisome Proliferator-Activated Receptors and Acute Lung Injury

Academic Editor: Jesse Roman
Received22 Dec 2006
Revised08 Feb 2007
Accepted02 May 2007
Published08 Jul 2007

Abstract

Peroxisome proliferator-activated receptors are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. PPARs regulate several metabolic pathways by binding to sequence-specific PPAR response elements in the promoter region of target genes, including lipid biosynthesis and glucose metabolism. Recently, PPARs and their respective ligands have been implicated as regulators of cellular inflammatory and immune responses. These molecules are thought to exert anti-inflammatory effects by negatively regulating the expression of proinflammatory genes. Several studies have demonstrated that PPAR ligands possess anti-inflammatory properties and that these properties may prove helpful in the treatment of inflammatory diseases of the lung. This review will outline the anti-inflammatory effects of PPARs and PPAR ligands and discuss their potential therapeutic effects in animal models of inflammatory lung disease.

References

  1. R. Hess, W. Stäubli, and W. Riess, “Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat,” Nature, vol. 208, no. 13, pp. 856–858, 1965. View at: Publisher Site | Google Scholar
  2. J. Vamecq and N. Latruffe, “Medical significance of peroxisome proliferator-activated receptors,” The Lancet, vol. 354, no. 9173, pp. 141–148, 1999. View at: Publisher Site | Google Scholar
  3. J. C. Corton, S. P. Anderson, and A. Stauber, “Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators,” Annual Review of Pharmacology and Toxicology, vol. 40, pp. 491–518, 2000. View at: Publisher Site | Google Scholar
  4. P. Dowell, J. E. Ishmael, D. Avram, V. J. Peterson, D. J. Nevrivy, and M. Leid, “Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor α interacting protein,” Journal of Biological Chemistry, vol. 274, no. 22, pp. 15901–15907, 1999. View at: Publisher Site | Google Scholar
  5. J. C. Fruchart, B. Staels, and P. Duriez, “The role of fibric acids in atherosclerosis,” Current Atherosclerosis Reports, vol. 3, no. 1, pp. 83–92, 2001. View at: Publisher Site | Google Scholar
  6. B. Desvergne, L. Michalik, and W. Wahli, “Be fit or be sick: peroxisome proliferator-activated receptors are down the road,” Molecular Endocrinology, vol. 18, no. 6, pp. 1321–1332, 2004. View at: Publisher Site | Google Scholar
  7. A. Fredenrich and P. A. Grimaldi, “PPAR delta: an uncompletely known nuclear receptor,” Diabetes and Metabolism, vol. 31, no. 1, pp. 23–27, 2005. View at: Publisher Site | Google Scholar
  8. A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006. View at: Publisher Site | Google Scholar
  9. C. A. Argmann, T.-A. Cock, and J. Auwerx, “Peroxisome proliferator-activated receptor γ: the more the merrier?,” European Journal of Clinical Investigation, vol. 35, no. 2, pp. 82–92, 2005. View at: Publisher Site | Google Scholar
  10. M. A. Lazar, “PPARγ, 10 years later,” Biochimie, vol. 87, no. 1, pp. 9–13, 2005. View at: Publisher Site | Google Scholar
  11. H. Sundvold, A. Brzozowska, and S. Lien, “Characterisation of bovine peroxisome proliferator-activated receptors γ1 and γ2: genetic mapping and differential expression of the two isoforms,” Biochemical and Biophysical Research Communications, vol. 239, no. 3, pp. 857–861, 1997. View at: Publisher Site | Google Scholar
  12. S. Ueki, Y. Matsuwaki, and H. Kayaba et al., “Peroxisome proliferator-activated receptor γ regulates eosinophil functions: a new therapeutic target for allergic airway inflammation,” International Archives of Allergy and Immunology, vol. 134, supplement 1, pp. 30–36, 2004. View at: Publisher Site | Google Scholar
  13. M. Hetzel, D. Walcher, M. Grüb, H. Bach, V. Hombach, and N. Marx, “Inhibition of MMP-9 expression by PPARγ activators in human bronchial epithelial cells,” Thorax, vol. 58, no. 9, pp. 778–783, 2003. View at: Publisher Site | Google Scholar
  14. H. J. Patel, M. G. Belvisi, D. Bishop-Bailey, M. H. Yacoub, and J. A. Mitchell, “Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy,” Journal of Immunology, vol. 170, no. 5, pp. 2663–2669, 2003. View at: Google Scholar
  15. R. Pawliczak, C. Han, X.-L. Huang, A. J. Demetris, J. H. Shelhamer, and T. Wu, “85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor γ activation in human lung epithelial cells,” Journal of Biological Chemistry, vol. 277, no. 36, pp. 33153–33163, 2002. View at: Publisher Site | Google Scholar
  16. G. R. Bernard, A. Artigas, and K. L. Brigham et al., “The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 3, part 1, pp. 818–824, 1994. View at: Google Scholar
  17. L. B. Ware and M. A. Matthay, “The acute respiratory distress syndrome,” New England Journal of Medicine, vol. 342, no. 18, pp. 1334–1349, 2000. View at: Publisher Site | Google Scholar
  18. Y. Sivan, C. Mor, S. Al-Jundi, and C. J. Newth, “Adult respiratory distress syndrome in severely neutropenic children,” Pediatric Pulmonology, vol. 8, no. 2, pp. 104–108, 1990. View at: Publisher Site | Google Scholar
  19. M. A. Matthay and J. P. Wiener-Kronish, “Intact epithelial barrier function is critical for the resolution of alveolar edema in humans,” American Review of Respiratory Disease, vol. 142, no. 6, pp. 1250–1257, 1990. View at: Google Scholar
  20. J. I. Sznajder, “Strategies to increase alveolar epithelial fluid removal in the injured lung,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 5 part 1, pp. 1441–1442, 1999. View at: Google Scholar
  21. W. M. Zapol, R. L. Trelstad, J. W. Coffey, I. Tsai, and R. A. Salvador, “Pulmonary fibrosis in severe acute respiratory failure,” American Review of Respiratory Disease, vol. 119, no. 4, pp. 547–554, 1979. View at: Google Scholar
  22. J. F. Tomashefski, “Pulmonary pathology of the adult respiratory distress syndrome,” Clinics in Chest Medicine, vol. 11, no. 4, pp. 593–619, 1990. View at: Google Scholar
  23. A. C. J. Windsor, C. J. Walsh, and P. G. Mullen et al., “Tumor necrosis factor-α blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1459–1468, 1993. View at: Google Scholar
  24. P. R. Colville-Nash, S. S. Qureshi, D. Willis, and D. A. Willoughby, “Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1,” Journal of Immunology, vol. 161, no. 2, pp. 978–984, 1998. View at: Google Scholar
  25. G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at: Publisher Site | Google Scholar
  26. R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002. View at: Google Scholar
  27. A. E. Lovett-Racke, R. Z. Hussain, and S. Northrop et al., “Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease,” Journal of Immunology, vol. 172, no. 9, pp. 5790–5798, 2004. View at: Google Scholar
  28. T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma,” Experimental Neurology, vol. 194, no. 1, pp. 267–278, 2005. View at: Publisher Site | Google Scholar
  29. H. Okamoto, T. Iwamoto, S. Kotake, S. Momohara, H. Yamanaka, and N. Kamatani, “Inhibition of NK-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 23, no. 3, pp. 323–330, 2005. View at: Google Scholar
  30. P. Delerive, K. De Bosscher, and S. Besnard et al., “Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1,” Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999. View at: Publisher Site | Google Scholar
  31. P. Delerive, P. Gervois, J.-C. Fruchart, and B. Staels, “Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators,” Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703–36707, 2000. View at: Publisher Site | Google Scholar
  32. E. Dyrøy, A. Yndestad, and T. Ueland et al., “Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor α-dependent and -independent pathways,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 7, pp. 1364–1369, 2005. View at: Publisher Site | Google Scholar
  33. S. Cuzzocrea, E. Mazzon, and R. Di Paola et al., “The role of the peroxisome proliferator-activated receptor-α (PPAR-α) in the regulation of acute inflammation,” Journal of Leukocyte Biology, vol. 79, no. 5, pp. 999–1010, 2006. View at: Publisher Site | Google Scholar
  34. C. Delayre-Orthez, J. Becker, and I. Guenon et al., “PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse,” Respiratory Research, vol. 6, p. 91, 2005. View at: Publisher Site | Google Scholar
  35. T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of peroxisome proliferator-activated receptor-α in acute pancreatitis induced by cerulein,” Immunology, vol. 118, no. 4, pp. 559–570, 2006. View at: Publisher Site | Google Scholar
  36. P. Jiang, J.-C. Wang, Y.-M. Zhao, and G.-S. Qian, “Influence and mechanism of peroxisome proliferation activated receptor-α expression induced by WY14643 in rat lung with acute lung injury,” Zhongguo Weizhongbing Jijiuyixue, vol. 18, no. 8, pp. 466–469, 2006. View at: Google Scholar
  37. T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor α in the development of bleomycin-induced lung injury,” Shock, vol. 24, no. 6, pp. 547–555, 2005. View at: Publisher Site | Google Scholar
  38. S. Cuzzocrea, N. S. Wayman, and E. Mazzon et al., “The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 attenuates the development of acute and chronic inflammation,” Molecular Pharmacology, vol. 61, no. 5, pp. 997–1007, 2002. View at: Publisher Site | Google Scholar
  39. S. Cuzzocrea, B. Pisano, and L. Dugo et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation,” European Journal of Pharmacology, vol. 483, no. 1, pp. 79–93, 2004. View at: Publisher Site | Google Scholar
  40. M. Abdelrahman, M. Collin, and C. Thiemermann, “The peroxisome proliferator-activated receptor-γ ligand 15-deoxy Δ12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock,” Shock, vol. 22, no. 6, pp. 555–561, 2004. View at: Publisher Site | Google Scholar
  41. S. Cuzzocrea, B. Pisano, and L. Dugo et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of nonseptic shock induced by zymosan in mice,” Critical Care Medicine, vol. 32, no. 2, pp. 457–466, 2004. View at: Publisher Site | Google Scholar
  42. D. Liu, B. X. Zeng, and Y. Shang, “Decreased expression of peroxisome proliferator-activated receptor γ in endotoxin-induced acute lung injury,” Physiological Research, vol. 55, no. 3, pp. 291–299, 2006. View at: Google Scholar
  43. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at: Publisher Site | Google Scholar
  44. S. Ohtsuka, M. Kakihana, H. Watanabe, T. Enomoto, R. Ajisaka, and Y. Sugishita, “Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension,” Journal of Hypertension, vol. 14, no. 11, pp. 1349–1355, 1996. View at: Publisher Site | Google Scholar
  45. R. M. Strieter, R. Wiggins, and S. H. Phan et al., “Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells,” Biochemical and Biophysical Research Communications, vol. 162, no. 2, pp. 694–700, 1989. View at: Publisher Site | Google Scholar
  46. H. Ishii, M. Ishibashi, M. Takayama, T. Nishida, and M. Yoshida, “The role of cytokine-induced neutrophil chemoattractant-1 in neutrophil-mediated remote lung injury after intestinal ischaemia/reperfusion in rats,” Respirology, vol. 5, no. 4, pp. 325–331, 2000. View at: Publisher Site | Google Scholar
  47. P. L. Khimenko, G. J. Bagby, J. Fuseler, and A. E. Taylor, “Tumor necrosis factor-α in ischemia and reperfusion injury in rat lungs,” Journal of Applied Physiology, vol. 85, no. 6, pp. 2005–2011, 1998. View at: Google Scholar
  48. M. Okada, S. F. Yan, and D. J. Pinsky, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets,” The FASEB Journal, vol. 16, no. 14, pp. 1861–1868, 2002. View at: Publisher Site | Google Scholar
  49. T. J. Standiford, V. C. Keshamouni, and R. C. Reddy, “Peroxisome proliferator-activated receptor-γ as a regulator of lung inflammation and repair,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 226–231, 2005. View at: Publisher Site | Google Scholar
  50. K.-I. Inoue, H. Takano, and R. Yanagisawa et al., “Effect of 15-deoxy-Δ12,14-prostaglandin J2 on acute lung injury induced by lipopolysaccharide in mice,” European Journal of Pharmacology, vol. 481, no. 2-3, pp. 261–269, 2003. View at: Publisher Site | Google Scholar
  51. H. A. Burgess, L. E. Daugherty, and T. H. Thatcher et al., “PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis,” Lung Cellular and Molecular Physiology, vol. 288, no. 6, pp. L1146–L1153, 2005. View at: Publisher Site | Google Scholar
  52. T. Genovese, S. Cuzzocrea, and R. Di Paola et al., “Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury,” European Respiratory Journal, vol. 25, no. 2, pp. 225–234, 2005. View at: Publisher Site | Google Scholar
  53. M. Ando, Y. Murakami, and F. Kojima et al., “Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin,” American Journal of Respiratory Cell and Molecular Biology, vol. 28, no. 5, pp. 582–591, 2003. View at: Publisher Site | Google Scholar

Copyright © 2007 Rosanna Di Paola and Salvatore Cuzzocrea. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

0 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.